Literature DB >> 17717292

Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease.

Marta Scatena1, Lucy Liaw, Cecilia M Giachelli.   

Abstract

Osteopontin (OPN) is a multifunctional molecule highly expressed in chronic inflammatory and autoimmune diseases, and it is specifically localized in and around inflammatory cells. OPN is a secreted adhesive molecule, and it is thought to aid in the recruitment of monocytes-macrophages and to regulate cytokine production in macrophages, dendritic cells, and T-cells. OPN has been classified as T-helper 1 cytokine and thus believed to exacerbate inflammation in several chronic inflammatory diseases, including atherosclerosis. Besides proinflammatory functions, physiologically OPN is a potent inhibitor of mineralization, it prevents ectopic calcium deposits and is a potent inducible inhibitor of vascular calcification. Clinically, OPN plasma levels have been found associated with various inflammatory diseases, including cardiovascular burden. It is thus imperative to dissect the OPN proinflammatory and anticalcific functions. OPN recruitment functions of inflammatory cells are thought to be mediated through its adhesive domains, especially the arginine-glycine-aspartate (RGD) sequence that interacts with several integrin heterodimers. However, the integrin receptors and intracellular pathways mediating OPN effects on immune cells are not well established. Furthermore, several studies show that OPN is cleaved by at least 2 classes of proteases: thrombin and matrix-metalloproteases (MMPs). Most importantly, at least in vitro, fragments generated by cleavage not only maintain OPN adhesive functions but also expose new active domains that may impart new activities. The role for OPN proteolytic fragments in vivo is almost completely unexplored. We believe that further knowledge of the effects of OPN fragments on cell responses might help in designing therapeutics targeting inflammatory and cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17717292     DOI: 10.1161/ATVBAHA.107.144824

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  228 in total

1.  Cholesterol in vascular and valvular calcification.

Authors:  L L Demer
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

2.  Activation of vascular smooth muscle parathyroid hormone receptor inhibits Wnt/beta-catenin signaling and aortic fibrosis in diabetic arteriosclerosis.

Authors:  Su-Li Cheng; Jian-Su Shao; Linda R Halstead; Kathryn Distelhorst; Oscar Sierra; Dwight A Towler
Journal:  Circ Res       Date:  2010-05-20       Impact factor: 17.367

Review 3.  The obesity of bone.

Authors:  Emanuela A Greco; Andrea Lenzi; Silvia Migliaccio
Journal:  Ther Adv Endocrinol Metab       Date:  2015-12       Impact factor: 3.565

4.  Effect of sleeve gastrectomy on osteopontin circulating levels and expression in adipose tissue and liver in rats.

Authors:  Andoni Lancha; Rafael Moncada; Víctor Valentí; Amaia Rodríguez; Victoria Catalán; Sara Becerril; Beatriz Ramírez; Leire Méndez-Giménez; Gema Frühbeck; Javier Gómez-Ambrosi
Journal:  Obes Surg       Date:  2014-10       Impact factor: 4.129

5.  Serum level of osteopontin as an inflammatory marker does not indicate disease activity or responsiveness to therapeutic treatments in patients with rheumatoid arthritis.

Authors:  Hye-In Ji; Sang-Hoon Lee; Ran Song; Hyung-In Yang; Yeon-Ah Lee; Seung-Jae Hong; Somi Kim; Yong-Beom Park; Soo-Kon Lee; Myung Chul Yoo; Kyoung Soo Kim
Journal:  Clin Rheumatol       Date:  2013-09-01       Impact factor: 2.980

6.  QCT Volumetric Bone Mineral Density and Vascular and Valvular Calcification: The Framingham Study.

Authors:  Jimmy J Chan; L Adrienne Cupples; Douglas P Kiel; Christopher J O'Donnell; Udo Hoffmann; Elizabeth J Samelson
Journal:  J Bone Miner Res       Date:  2015-05-06       Impact factor: 6.741

7.  10-years experience with the Athero-Express study.

Authors:  Willem E Hellings; Frans L Moll; Dominique P V de Kleijn; Gerard Pasterkamp
Journal:  Cardiovasc Diagn Ther       Date:  2012-03

8.  Soluble levels of osteopontin in patients with Behcet's disease: association with disease activity and vascular involvement.

Authors:  Iman H Bassyouni; Mohammed M El-Wakd; Rasha H Bassyouni
Journal:  J Clin Immunol       Date:  2012-10-25       Impact factor: 8.317

9.  Osteocalcin, under-carboxylated osteocalcin and osteopontin are not associated with gestational diabetes mellitus but are inversely associated with leptin in non-diabetic women.

Authors:  R Saucedo; G Rico; G Vega; L Basurto; L Cordova; R Galvan; M Hernandez; E Puello; A Zarate
Journal:  J Endocrinol Invest       Date:  2014-12-06       Impact factor: 4.256

10.  Increase of osteopontin plasma concentrations after bariatric surgery independent from inflammation and insulin resistance.

Authors:  Georg Schaller; Yoshimasa Aso; Gerit-Holger Schernthaner; Hans-Peter Kopp; Toshihiko Inukai; Stefan Kriwanek; Guntram Schernthaner
Journal:  Obes Surg       Date:  2008-05-02       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.